- Home
- GHRS vs PAHC Comparison
GHRS vs PAHC Comparison
Compare GHRS & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- PAHC
- Stock Information
- Founded
- GHRS 2018
- PAHC 1946
- Country
- GHRS Ireland
- PAHC United States
- Employees
- GHRS N/A
- PAHC N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- PAHC Biotechnology: Pharmaceutical Preparations
- Sector
- GHRS Health Care
- PAHC Health Care
- Exchange
- GHRS Nasdaq
- PAHC Nasdaq
- Market Cap
- GHRS 868.7M
- PAHC 871.9M
- IPO Year
- GHRS 2021
- PAHC 2014
- Fundamental
- Price
- GHRS $11.06
- PAHC $21.46
- Analyst Decision
- GHRS Strong Buy
- PAHC Sell
- Analyst Count
- GHRS 7
- PAHC 4
- Target Price
- GHRS $30.86
- PAHC $21.00
- AVG Volume (30 Days)
- GHRS 257.0K
- PAHC 279.9K
- Earning Date
- GHRS 05-02-2025
- PAHC 05-07-2025
- Dividend Yield
- GHRS N/A
- PAHC 2.22%
- EPS Growth
- GHRS N/A
- PAHC 30.53
- EPS
- GHRS N/A
- PAHC 0.48
- Revenue
- GHRS N/A
- PAHC $1,106,080,000.00
- Revenue This Year
- GHRS N/A
- PAHC $28.33
- Revenue Next Year
- GHRS N/A
- PAHC $10.57
- P/E Ratio
- GHRS N/A
- PAHC $45.46
- Revenue Growth
- GHRS N/A
- PAHC 12.63
- 52 Week Low
- GHRS $6.00
- PAHC $12.17
- 52 Week High
- GHRS $20.50
- PAHC $26.55
- Technical
- Relative Strength Index (RSI)
- GHRS 45.98
- PAHC 43.40
- Support Level
- GHRS $10.20
- PAHC $21.38
- Resistance Level
- GHRS $13.21
- PAHC $22.53
- Average True Range (ATR)
- GHRS 0.90
- PAHC 0.74
- MACD
- GHRS 0.07
- PAHC -0.05
- Stochastic Oscillator
- GHRS 28.56
- PAHC 38.55
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
About PAHC Phibro Animal Health Corporation
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.